MX2009011022A - Uso de sustratos como chaperonas farmacologicas. - Google Patents

Uso de sustratos como chaperonas farmacologicas.

Info

Publication number
MX2009011022A
MX2009011022A MX2009011022A MX2009011022A MX2009011022A MX 2009011022 A MX2009011022 A MX 2009011022A MX 2009011022 A MX2009011022 A MX 2009011022A MX 2009011022 A MX2009011022 A MX 2009011022A MX 2009011022 A MX2009011022 A MX 2009011022A
Authority
MX
Mexico
Prior art keywords
substrates
pharmacological chaperones
chaperones
pharmacological
enhancing
Prior art date
Application number
MX2009011022A
Other languages
English (en)
Inventor
Benjamin Mugrage
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2009011022A publication Critical patent/MX2009011022A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un método para mejorar la actividad de enzimas lisosomales utilizando sustratos que son derivados de sustratos naturales como chaperonas farmacológicas.
MX2009011022A 2007-04-13 2008-04-11 Uso de sustratos como chaperonas farmacologicas. MX2009011022A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91171007P 2007-04-13 2007-04-13
PCT/US2008/060094 WO2008128089A1 (en) 2007-04-13 2008-04-11 Use of substrates as pharmacological chaperones

Publications (1)

Publication Number Publication Date
MX2009011022A true MX2009011022A (es) 2010-01-13

Family

ID=39864340

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011022A MX2009011022A (es) 2007-04-13 2008-04-11 Uso de sustratos como chaperonas farmacologicas.

Country Status (7)

Country Link
US (1) US20100197018A1 (es)
EP (1) EP2137204A4 (es)
JP (1) JP2010523160A (es)
AU (1) AU2008240205A1 (es)
CA (1) CA2684042A1 (es)
MX (1) MX2009011022A (es)
WO (1) WO2008128089A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022461A1 (en) * 2008-08-29 2010-03-04 Children, Youth And Women's Health Service Sulphated sugars to increase activity of sulphatases en lysosomal storage disorders
AU2010254092B2 (en) * 2009-05-26 2015-11-12 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US9206457B2 (en) * 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
WO2012027612A1 (en) * 2010-08-25 2012-03-01 Michael Gelb Mass spectrometric compositions and methods for lysosomal storage disease screening
JP2017195786A (ja) * 2016-04-25 2017-11-02 国立大学法人 熊本大学 細胞内酵素タンパク質の構造異常の正常化方法、細胞内酵素タンパク質の構造異常の検出方法、及び、遺伝性代謝病の治療方法ならびにその治療効果の予測・評価方法
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7927587B2 (en) * 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
AU2004293115A1 (en) * 2003-11-25 2005-06-09 Mount Sinai School Of Medicine Of New York University Chaperone-based therapy for Niemann-Pick disease

Also Published As

Publication number Publication date
WO2008128089A1 (en) 2008-10-23
CA2684042A1 (en) 2008-10-23
US20100197018A1 (en) 2010-08-05
JP2010523160A (ja) 2010-07-15
AU2008240205A1 (en) 2008-10-23
EP2137204A1 (en) 2009-12-30
EP2137204A4 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
WO2011011366A3 (en) Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
HK1208452A1 (en) Pyrazolo pyridine derivatives as nadph oxidase inhibitors nadph
HK1179871A1 (en) Pyrazolo pyridine derivatives as nadph oxidase inhibitors nadph
EP2288610B8 (en) Azetidine and cyclobutane derivatives as jak inhibitors
HK1193974A1 (zh) 吡唑並吡啶衍生物作為 氧化酶抑制劑
SI1848718T1 (sl) Inhibitorji E1 aktivacijskih enzimov
HK1159096A1 (en) Pyrazolo pyridine derivatives as nadph oxidase inhibitors nadph
HK1166308A1 (zh) 激活酶抑制劑
WO2011113798A3 (en) Inhibitors of semicarabazide - sensitive amine oxidase
HK1159092A1 (en) Pyrazolo pyridine derivatives as nadph oxidase inhibitors nadph
PL2772543T3 (pl) Enzymatyczny proces wytwarzania beta-santalenu i odpowiadającego mu enzymu
HU0402444D0 (en) Process for enhancing the biogas production of thermophyl anagrobic fermenter
MX2009011022A (es) Uso de sustratos como chaperonas farmacologicas.
EP2443231A4 (en) GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM UMBILICAL BLOOD
ZA201001052B (en) Process for the enantioselective enzymatic reduction of intermediates
WO2011005289A3 (en) Methods and kits for measuring enzyme activity
ZA200904235B (en) Method for the enantioselective enzymatic reduction of secodione derivatives
EP2435558A4 (en) PRODUCTION OF HEAVY INDUCED PLURIPOTENT STEM CELLS GENERALLY CORRECTED
GB2452892B (en) Process for culturing bacteria of the piscirickettsia genus
PL2029740T3 (pl) Zastosowanie polisacharydów do promowania aktywności enzymatycznej
MX2010003838A (es) Metodo para preparar (6r)-3-hexil-4-hidroxi-6-undecil-5,6-dihidrop iran-2-ona, e intermediario utilizado en el metodo.
NZ587553A (en) A new class of chloroflexi-iike thermophilic cellulose degrading bacteria
TW200745335A (en) Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
UA40128U (ru) Способ лечения хронического панкреатита
AU2013204601C1 (en) Process for the synthesis of E1 activating enzyme inhibitors

Legal Events

Date Code Title Description
FG Grant or registration